info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Purchase Channels for Mavacamten (Camzyos)?
500
Article source: Seagull Pharmacy
Jan 09, 2026

Mavacamten (Camzyos) is the world’s first approved cardiac myosin inhibitor for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), and its standardized use is directly related to therapeutic efficacy and safety.

What Are the Purchase Channels for Mavacamten (Camzyos)?

Overseas Purchase

Patients can choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries/regions where mavacamten has been approved for marketing.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budget plans in advance before purchase.

Purchase via Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels, as well as professional consultation and guidance services.

Precautions for Mavacamten (Camzyos) Administration

Cardiac Function Monitoring Requirements

The left ventricular ejection fraction (LVEF) must be ≥ 55% before the initiation of treatment.

Treatment must be immediately discontinued if LVEF drops below 50% during the course of therapy.

Continuous monitoring of the Valsalva left ventricular outflow tract gradient is required.

Contraindicated Drug Screening

Potent CYP2C19 inhibitors.

Moderate to potent CYP2C19 inducers.

Moderate to potent CYP3A4 inducers.

Identification of Authentic and Counterfeit Mavacamten (Camzyos)

Verification of Drug Packaging and Appearance

Authentic mavacamten is formulated as hard capsules, available in four strengths: 2.5 mg, 5 mg, 10 mg, and 15 mg.

The capsule body is opaque white, printed with the word “Mava”.

The capsule cap is opaque, printed with the dosage strength. The cap color varies by strength: purple for 2.5 mg, yellow for 5 mg, pink for 10 mg, and gray for 15 mg.

Carefully check whether the drug name, dosage, manufacturer information (Bristol-Myers Squibb), batch number, and expiration date printed on the packaging are clear and complete.

Vigilance should be exercised against any products with shoddy packaging, blurred printing, color deviations, or incomplete information.

Identification of Quality Abnormalities

The drug should be stored at a temperature between 20°C and 25°C.

If capsule breakage, abnormal discoloration, or packaging damage is found, the use of the drug should be suspended immediately.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Mavacamten(Camzyos)
Mavacamten(Camzyos)
CAMZYOS (mavacamten) is specifically indicated for the treatment of adult...
WeChat Scan
Free Inquiry
Recommended Articles
Adverse Reactions of Trametinib (Mekinist)
Trametinib (Mekinist) is a targeted therapy drug that demonstrates significant efficacy in the treatment of BRAFV600E or V600K mutation-positive melanoma, but the associated adverse reactions require ...
What are the precautions for Trametinib (Mekinist) administration?
Trametinib (Mekinist) is a reversible inhibitor of MEK1 and MEK2 kinases, playing a vital role in the treatment of BRAFV600E or V600K mutation-positive melanoma.What are the precautions for Trametinib...
Dosage and Administration of Trametinib (Mekinist)
Trametinib (Mekinist) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma that is confirmed to harbor BRAF V600E or V600K mutations by an FDA-approve...
What Are the Indications for Trametinib (Mekinist)?
Trametinib (Mekinist) is a kinase inhibitor. As a representative targeted drug in the era of precision medicine, it has demonstrated favorable clinical value in the treatment of melanoma.What Are the ...
What Are the Indications for Mavacamten (Camzyos)?
Mavacamten (Camzyos) is an oral cardiac myosin inhibitor that received its first approval in the United States in 2022. As an innovative therapy, it offers a new treatment direction for patients with ...
Dosage and Administration of Camzyos (Mavacamten)
Camzyos (Mavacamten) is a cardiac myosin inhibitor approved in the United States in 2022. It is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (...
What Are the Precautions for Mavacamten (Camzyos) Administration?
Mavacamten (Camzyos) is an innovative drug indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, and it belongs to the class of cardiac myosin inhibitors. As a prescripti...
Side Effects of Mavacamten (Camzyos)
Mavacamten (Camzyos) is a medication indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). As a drug with a unique mechanism of action, mavacamt...
Related Articles
Side Effects of Mavacamten (Camzyos)
Mavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), New York Heart Association (NYHA) functional cl...
What are the precautions for mavacamten (Camzyos)?
Mavacamten (Camzyos) is a novel cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) of New York Heart Association (NYHA) funct...
What are the Precautions for Mavacamten (Camzyos) Administration?
Mavacamten (Camzyos) is a novel cardiac myosin inhibitor indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) of New York Heart Association (NYH...
Adverse Effects of Mavacamten (Camzyos)
Mavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of adult patients with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy...
Side Effects of Mavacamten (Camzyos)
Mavacamten (Camzyos) is a medication indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). As a drug with a unique mechanism of action, mavacamt...
What Are the Precautions for Mavacamten (Camzyos) Administration?
Mavacamten (Camzyos) is an innovative drug indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, and it belongs to the class of cardiac myosin inhibitors. As a prescripti...
Dosage and Administration of Camzyos (Mavacamten)
Camzyos (Mavacamten) is a cardiac myosin inhibitor approved in the United States in 2022. It is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (...
What Are the Indications for Mavacamten (Camzyos)?
Mavacamten (Camzyos) is an oral cardiac myosin inhibitor that received its first approval in the United States in 2022. As an innovative therapy, it offers a new treatment direction for patients with ...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • haiousales@gmail.com
Welcome to consult
Seagull Pharmacy.,Ltd All rights reserved